Lemaitre Vascular INC 8-K filings

LeMaitre Vascular announced robust Q2 2026 financial results, exceeding expectations with 10% sales growth, improved gross margins, and a 23% increase in EPS, alongside positive future guidance.

LeMaitre Vascular announced robust Q1 2026 financial results, exceeding expectations with significant sales and EPS growth, and increased its full-year guidance.

LeMaitre Vascular announces director Bridget Ross will not seek re-election, with David B. Roberts nominated to fill a Class II director role and conditionally resign from Class I.

LeMaitre Vascular, Inc. announced robust Q4 2025 financial results, including 16% sales growth and 47% operating income growth, alongside a 25% increase in its quarterly dividend and a new $100 million share repurchase program.

LeMaitre Vascular's Board of Directors has decided to hold future Say-on-Pay votes on an annual basis, aligning with stockholder preference.

LeMaitre Vascular, Inc. announced robust Q3 2025 financial results, driven by double-digit sales growth and increased profitability, leading to an upward revision of its full-year guidance.

LeMaitre Vascular, Inc. announced robust Q2 2025 financial results, including a 15% sales increase and a 16% rise in diluted EPS, leading to an upward revision of its full-year guidance.

LeMaitre Vascular, Inc. announced the successful outcomes of its 2025 Annual Meeting of Stockholders, where all proposed matters, including the election of three Class I directors and the ratification of its independent auditor, were approved.

LeMaitre Vascular announces a strong Q1 2025 with sales up 12%, raises full-year guidance, and declares a $0.20/share quarterly dividend.

LeMaitre Vascular announces a robust Q4 2024 with significant sales growth, margin improvement, and increased dividend, alongside optimistic financial guidance for 2025.

LeMaitre Vascular, Inc. announces the appointment of Dorian LeBlanc as its new Chief Financial Officer, effective March 10, 2025.

LeMaitre Vascular, Inc. has successfully completed a $172.5 million offering of convertible senior notes to bolster working capital and explore strategic acquisitions.

LeMaitre Vascular has announced the pricing of a $150 million private offering of convertible senior notes due in 2030.

LeMaitre Vascular plans to raise $150 million through a private offering of convertible senior notes due in 2030.

LeMaitre Vascular announced robust Q3 2024 financial results, including a 16% increase in sales and a 43% jump in operating income, while also raising its full-year guidance.

LeMaitre Vascular, Inc. announces the retirement of its CFO, Joseph P. Pellegrino, Jr., effective March 7, 2025, while reaffirming its previously issued financial guidance.

LeMaitre Vascular announced robust Q2 2024 financial results, including a significant increase in sales and profitability, and raised its full-year guidance.

LeMaitre Vascular's shareholders approved an amended stock option plan and re-elected three directors, while also rejecting a director's resignation after a vote.

LeMaitre Vascular announced robust Q1 2024 financial results, including a 14% increase in sales and a 64% jump in net income, alongside an increased dividend and raised full-year guidance.

LeMaitre Vascular announced robust Q4 2023 results with significant growth in sales, gross margin, and operating income, alongside a new share repurchase program and increased dividend.